Opicapone
Indication
Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors
Amber level 0
Brand:
Ongentys ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
Opicapone is recommended as a second line catechol-o-methyltransferase [COMT] inhibitor in adult patients with Parkinson’s disease with “end of dose” motor fluctuations who cannot be stabilised on levodopa/DDCI inhibitors and who fail to respond to or are intolerant of entacapone, where tolcapone is being considered.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: